- Details
- Christopher Wallis and Zachary Klaassen discuss the OMNIVORE study published in the Journal of Clinical Oncology. This phase II response-adaptive trial investigated the rational application of immune checkpoint blockade in renal cell carcinoma. Biographies: Christopher J.D. Wallis, MD, Ph.D., Assistant Professor in the Division of Urology at the University of Toronto. Zachary Klaassen, MD, MSc, Ur...
|
- Details
- Zachary Klaassen and Christopher Wallis discuss the abstract "MRI-Targeted or Standard Biopsy in Prostate Cancer Screening," in this UroToday Journal Club. Magnetic resonance imaging (MRI) with targeted biopsy has shown the potential to address the challenge of overdiagnosis in prostate cancer screening. Biographies: Christopher J.D. Wallis, MD, Ph.D., Assistant Professor in the Division of Urolog...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss a publication about 225Actinium PSMA-617 and 177Lutetium PSMA-617 tandem therapy in metastatic castration-resistant prostate cancer (mCRPC) patients who have previously been treated with 177Lutetium PSMA-617 monotherapy. Biographies: Christopher J.D. Wallis, MD, Ph.D., Assistant Professor in the Division of Urology at the University of Toronto. Zacha...
|
- Details
- Christopher Wallis and Zachary Klaassen review the published OLIGOPELVIS GETUG P07 trial, a multicenter phase II trial of combined high-dose salvage radiotherapy and hormone therapy in oligorecurrent pelvic node relapses in prostate cancer. The hypothesis here is that intervention at the time of oligometastatic disease with treatment of these metastatic sites, may actually be curative rather than...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss a Journal of Clinical Oncology publication entitled, "Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer." The goal of this study was to derive a circulating tumor cells (CTCs)-based liquid biopsy transcriptional assay capable of measuring resistance mechan...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss an update on the CARMENA trial. CARMENA was a phase III trial in 450 patients with metastatic renal cell carcinoma (mRCC) enrolled from 2009 to 2017. The objective of this study was to provide updated overall survival (OS) outcomes of CARMENA and assess whether some subgroups may still benefit from upfront cytoreductive nephrectomy. Biographies: Chri...
|
- Details
- Christopher Wallis and Zachary Klaassen review the JAMA Oncology publication entitled, "Assessment of Prostate Cancer Treatment Among Black and White Patients During the COVID-19 Pandemic." The authors of this publication assessed the association between race and prostate cancer care delivery for Black and White patients during the first wave of the COVID-19 pandemic. Biographies: Christopher J.D....
|
- Details
- Christopher Wallis and Zachary Klaassen focus this discussion on the article published in The Lancet titled "Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound)." The authors of this study aimed to assess pain...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss the publication in the Lancet analyzing new data from the STAMPEDE trial of two randomized controlled phase 3 trials done in a multiarm, multistage platform protocol to assess the efficacy of adding abiraterone and prednisolone alone or with enzalutamide to androgen-deprivation therapy (ADT) in men with high-risk non-metastatic prostate cancer. Biogr...
|
- Details
- Christopher Wallis and Zachary Klaassen highlight the multicentre, open-label, phase 2 GALAHAD trial. In this trial, the authors evaluated the anti-tumour activity and safety of the PARP inhibitor niraparib in patients with metastatic castration-resistant prostate cancers and DNA repair gene defects (DRDs) who progressed on previous treatment with an androgen signaling inhibitor and a taxane. Biog...
|
